Back to Top

Vaccine (Vaccine)

Publisher :

Elsevier Ltd.

Scopus Profile
Peer reviewed only
Scopus Profile
Open Access
  • Immunology
  • Microbiology
  • Virology
  • +5

e-ISSN :

1873-2518

Issue Frequency :

Monthly

Impact Factor :

4.5

p-ISSN :

0264-410X

Est. Year :

1983

Mobile :

31204853911

Country :

Netherlands The

Language :

English

APC :

YES

Impact Factor Assignee :

Google Scholar

Email :

angela.rasmussen@usask.ca

Journal Descriptions

The official journal of The Japanese Society for Vaccinology. Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions. We also invite authors to submit relevant basic science and clinical reviews, methodological articles, opinion and commentary pieces, visual pieces, and letters. Authors are required to consult the Guide for Authors as the submission guidelines are dynamic and therefore subject to change. Vaccine has an open access companion journal titled Vaccine: X. The Editors retain the right to desk reject submissions without peer review when it is clear that the Guide for Authors has not been consulted.


Vaccine (Vaccine) is :

International, Peer-Reviewed, Open Access, Refereed, Immunology, Microbiology, Virology, Allergology and Rheumatology, Infectious Diseases, Public Health and Health Policy, Veterinary Medicine, Veterinary Science , Online or Print, Monthly Journal

UGC Approved, ISSN Approved: P-ISSN - 0264-410X, E-ISSN - 1873-2518, Established in - 1983, Impact Factor - 4.5

Not Provide Crossref DOI

Indexed in Scopus, WoS, DOAJ, PubMed

Not indexed in UGC CARE

Publications of Vaccine

Reduction of HPV infections through vaccination among at-risk urban adolescents

Introduction Human papillomavirus (HPV) vaccine trials have demonstrated high efficacy in preventing HPV infections and HPV related disease in females ages 16–26. However, there is no sou...

Human papillomavirus vaccine communication: Perspectives of 11–12 year-old girls, mothers, and clinicians

Objectives Because little is known about the content of human papillomavirus (HPV) vaccine-related discussions with young adolescent girls in clinical settings, we explored communication be...

Establish Your Own Journal Without the Expense!

OJSCloud offers a complete, free setup to get you publishing.

Start Your Free Journal!
free profile